

Product sales

Full year 2024 product sales

The following table provides the top 20 product net sales from continuing operations in 2024, as well as the change compared with 2023:

Brands	Net Sales (USD m)	% change (USD)	% change (cc ¹)	Brand classification by therapeutic area or established brands
<i>Entresto</i>	7,822	30	31	Cardiovascular, renal and metabolic
<i>Cosentyx</i>	6,141	23	25	Immunology
<i>Kesimpta</i>	3,224	49	49	Neuroscience
<i>Kisqali</i>	3,033	46	49	Oncology
<i>Promacta/Revolade</i>	2,216	-2	-1	Oncology
<i>Tafinlar + Mekinist</i>	2,058	7	9	Oncology
<i>Jakavi</i>	1,936	13	15	Oncology
<i>Tasigna</i>	1,671	-10	-8	Oncology
<i>Xolair</i> ²	1,643	12	15	Immunology
<i>Ilaris</i>	1,509	11	14	Immunology
<i>Pluvicto</i>	1,392	42	42	Oncology
<i>Sandostatin Group</i>	1,279	-3	-1	Established brands
<i>Zolgensma</i>	1,214	0	2	Neuroscience
<i>Lucentis</i>	1,044	-29	-28	Established brands
<i>Leqvio</i>	754	112	114	Cardiovascular, renal and metabolic
<i>Lutathera</i>	724	20	20	Oncology
<i>Exforge Group</i>	703	-1	2	Established brands
<i>Scemblix</i>	689	67	68	Oncology
<i>Galvus Group</i>	602	-13	-6	Established brands
<i>Diovan Group</i>	590	-4	0	Established brands

Source URL: <https://prod1.novartis.com/investors/financial-data/product-sales>

List of links present in page

1. <https://prod1.novartis.com/investors/financial-data/product-sales>